ARID1A and endometrial carcinoma: ARID1A is likely to be pathogenic rather than a ‘passenger’ mutation in these MSI endometrial cancers, as ARID1A loss was found in only 14% of Lynch syndrome MSI endometrial carcinomas compared to 75% of sporadic MSI endometrial carcinomas in one study [60].